How COVID-19 Resources Will Shape the Future of Rapid Testing

article image
ARTICLE SUMMARY:

The 2020 launch of the RADx program has resulted in an unprecedented influx of funding and attention into the diagnostics industry, which has led to technological innovation and business shifts that affect far more than COVID-19 treatment.

Through much of the pandemic, diagnostic testing faced enormous challenges, including lack of understanding of clinical utility, scaling operations, distribution, and supply chain issues. In April 2020, the NIH set up the Rapid Acceleration of Diagnostics (RADx) program, which leverages expertise from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and other government agencies to speed development, validation, and commercialization of point-of-care and home tests and improve clinical laboratory detection of SARS-CoV-2.

×

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?


Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.

All-Access

Questions?

We're here to help! Please contact us at: